IGF2-derived miR-483 mediated oncofunction by suppressing DLC-1 and associated with colorectal cancer

Hengmi Cui1,2,7*, Yuan Liu2,3,5,*, Jingrui Jiang2,3,6,*, Yangyang Liu1,2, Zhe Yang1,2, Shaogen Wu2,3, Wangsen Cao2, Isabelle H. Cui4, Chenggong Yu2,3

1Institute of Epigenetics and Epigenomics, Institute of Comparative Medicine and College of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu, China
2Laboratory of Epigenetics & Epigenomics, Medical School, Nanjing University, Nanjing, China
3Department of Gastroenterology, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China
4Department of Pathology and Laboratory Medicine, New York Presbyterian-Weill Cornell Medicine, New York, USA
5Quzhou People’s Hospital, Quzhou, Zhejiang, China
6Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China
7Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China

*These authors have contributed equally to this work

Correspondence to: Hengmi Cui, email: hmcui@yzu.edu.cn
Chenggong Yu, email: chenggong.yu@gmail.com

Keywords: IGF2, miR-483, colorectal cancer, DLC-1

Received: February 15, 2016  Accepted: June 09, 2016  Published: June 27, 2016

ABSTRACT

Emerging evidence indicates that IGF2 plays an important role in various human malignancies, including colorectal cancer (CRC). Hsa-miR-483 is located within intron 7 of the IGF2 locus. However, the mechanism by which increased IGF2 induces carcinogenesis remains largely elusive. DLC-1 has been identified as a candidate tumor suppressor. In this study, we aimed at investigating whether miR-483 transcription is IGF2-dependent, identifying the functional target of miR-483, and evaluating whether tissue and serum miR-483-3p or miR-483-5p levels are associated with CRC. Our results showed that sequences upstream miR-483 had undetectable promoter activity and levels of IGF2, miR-483-3p, and miR-483-5p were synchronously increased in CRC tissues. Positive correlations between IGF2 and miR-483-3p (r=0.4984, ***p<0.0001), and between IGF2 and miR-483-5p (r=0.6659, ***p<0.0001) expression were found. In addition, patients with CRC had a significantly higher serum miR-483-5p level (*p<0.05) compared to normal controls. DLC-1 expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR-483-3p. Our results suggest that IGF2 may exert its oncofunction, at least partly, through its parasitic miR-483 which suppressed DLC-1 in CRC cells. Thus, miR-483 might serve as a new target for therapy and a potential biomarker for the detection of colorectal cancer.

INTRODUCTION

The incidence and mortality rates of colorectal cancer (CRC) have been increasing rapidly in the past several decades, making it the third most common cancer worldwide [1]. Early detection of CRC appears to be a key measure in reducing cancer related deaths. Fecal occult-blood testing (FOBT), colonoscopy and stool DNA test have been available as screening tests for CRC. However, none of these methods has been well accepted as screening tools due to their low adherence rates, high cost and low sensitivity [1]. An ideal screening test should have a high sensitivity and specificity and should also be safe and affordable so that it can be broadly utilized. IGF2 (insulin-like growth factor II) is an imprinted gene which is normally expressed exclusively from the paternal allele. An abnormal high expression...
of IGF2 has been involved in a variety of cancers, but is expressed at a low level in most normal tissue [2]. We and others have previously reported that biallelic expression of the IGF2 gene, also known as loss of imprinting (LOI), usually accompanying the overexpression of IGF2, occurs in 40% to 50% of tumors, including CRC, and is thought to be an early event in carcinogenesis [3-8]. microRNAs (miRNAs) are 17-24 nucleotide non-coding RNA molecules that regulate a variety of cellular processes including cell differentiation, cell cycle progression and apoptosis [9]. miRNAs have been demonstrated to play an important role in the multistep processes of carcinogenesis either by oncogenic or tumor suppressor function [10]. The study of miRNA has been extended into many kinds of tumors, including CRC. Recent findings have shown that the IGF2 locus harbors a miRNA, miR-483, within the seventh intron; a positive correlation was found between IGF2 and miR-483-3p and miR-483-5p expression in the tumors studied [2, 11]. Tumor-associated RNAs have been reported in the serum and/or plasma of cancer patients. Ng et al. showed that miR-92 is significantly elevated in the plasma of CRC patients and might be a potential noninvasive molecular marker for CRC [12]. Accordingly, several subsequent studies have shown that miR-483 can serve as potential biomarkers for various cancers [13-15], however the mechanism by which elevated miR-483 impacts the development of cancer remains unclear. The DLC-1 (Deleted in liver cancer 1) gene was originally discovered as a potential tumor suppressor frequently deleted in hepatocellular carcinoma. Its expression is lost or decreased in various cancers including liver, breast, lung, stomach, colon and prostate cancers [16]. Research on DLC-1 has focused on its multiple biological functions in regulating cell skeleton modulation, motion, proliferation and migration [17, 18]. In this study, we evaluated the feasibility of using tissue and serum miR-483-3p/5p as a noninvasive diagnostic test for early detection of CRC and explored the oncrolefntion of miR-483 and the mechanism of colorectal carcinogenesis through the overexpression of the IGF2 gene and miR-483.

RESULTS

Enhanced expression of both miR-483 and IGF2 in CRC tissues

We examined the expression levels of miR-483-3p, miR-483-5p and IGF2 in 77 cases of primary colorectal cancers and their adjacent non-cancerous tissues by quantitative RT PCR. When compared to the matched normal tissues, we found that the expression level of IGF2 was significantly increased in CRC tissues (*p<0.05; Figure 1A). Meanwhile, 59 out of 77 cases showed higher miR-483-3p expression (76.62%, p<0.0001; Figure 1B) and 62 had higher miR-483-5p expression (80.52%, p<0.0001; Figure 1C). These results suggest that miR-483-3p and miR-483-5p have a similar expression pattern as the IGF2 gene, and all are increased in CRC.

Based on the miRNA levels in CRC and matched normal tissues, the Receiver Operating Characteristic Curve (ROC) had an Area Under the Curve (AUC) value of 0.733 for miR-483-3p (95% CI: 0.6542 to 0.8125; p<0.0001; Figure 1D) and 0.714 for miR-483-5p (95% CI: 0.6332 to 0.7940; p<0.0001; Figure 1E). A cut-off value, which maximizes the sum of sensitivity and specificity, of 9.22 was selected for miR-483-3p and 12.27 for miR-483-5p. The sensitivity and specificity of miR-483-3p in patients with CRC were 76.62% and 62.34%, and the sensitivity and specificity of miR-483-5p were 51.59% and 84.42%, respectively.

miR-483 was coexpressed with IGF2

Since miR-483 is located within the IGF2 gene, we hypothesized that miR-483 may be coexpressed with the IGF2 gene. When compared their expression levels using TagMan RT-qPCR, we found positive correlations between IGF2 mRNA and miR-483-3p (r=0.4984, p<0.0001; Figure 2A), and between IGF2 mRNA and miR-483-5p expression (r=0.6659, p<0.0001; Figure 2B). In order to determine whether miR-483 was co-transcribed with the IGF2 gene, we used the pGL3 Luciferase Reporter vector to detect the putative promoter activity of the 2kb sequences upstream miR-483 and compared that to the luciferase activities of the basic vector or pGL3 control vector; the putative miR-483 promoter activity was undetectable, suggesting that miR-483 may be co-transcribed with the host gene IGF2 due to a lack of its own promoter (Figure 3A-3C).

miR-483-5p as a potential CRC marker

In order to select suitable internal controls for serum miRNA detection, the serum expression levels of both U6 snRNA and miR-16 were tested (Supplementary Figures S1A-S1B). We found that only miR-16 expression was consistently detected in all serum samples. No significant difference was detected in the raw Ct values of miR-16 among the normal control (NC) and CRC groups (p=0.4050), whereas the U6 snRNA Ct value was significantly higher in the CRC group compared to that of the NC (p<0.0001). Therefore, miR-16 was selected as the internal normalization control for the serum miRNA detection.

When comparing serum miR-483-3p and miR-483-5p levels in patients with CRC and healthy controls (CRC, n=55, NC, n=31), we found that serum miR-483-5p level was increased in CRC patients compared to NC (p<0.01), but surprisingly there was no significant difference in serum miR-483-3p level between CRC patients and NC (Figure 4A, 4B). ROC curve analysis was utilized to analyze the diagnostic accuracy of serum miR-483-3p and miR-483-5p. The results showed the miR-483-5p AUC for CRC and control was 0.712 (95% CI: 0.6020–0.8220; p=0.0012, Figures 4D),
Figure 1: Overexpression of IGF2, miR-483-3p and miR-483-5p in colorectal cancers compared to matched normal tissues. A. Relative expression levels of IGF2 in colorectal cancer and matched normal tissues (n=77). B. Relative miR-483-3p expression levels in colorectal cancer and matched normal tissues (n=77). C. Relative miR-483-5p expression levels in colorectal tumor and matched normal tissues (n=77). The expression levels of both miR-483-3p and miR-483-5p were normalized to U6 snRNA and are presented as fold changes ($2^{-\Delta\Delta Ct}$) above NC. Receiver operating characteristics (ROC) curves based on D. miR-483-3p and E. miR-483-5p were plotted to discriminate between normal and CRC patients. MiR-483-3p and miR-483-5p yield an area under the curve (AUC) value of 0.7333 and 0.7136, respectively. *, p<0.05 and ***, p<0.001 indicate significant or very significant differences in expression levels between paired samples determined by the Wilcoxon matched pairs test.

Figure 2: A positive correlation between IGF2 and miR-483 in CRC tissues. The miR-483-3p and miR-483-5p expression levels compared with IGF2 expression A. miR-483-3p expression compared with IGF2 expression by RT-qPCR (Rs= 0.4984, p< 0.0001); B. miR-483-5p expression compared with IGF2 expression by RT-qPCR (Rs= 0.6659, p< 0.0001). The Pearson correlation test was used to determine statistical significance.
Figure 3: Identification of a potential promoter of miR-483 by luciferase activity assays in HEK293T(A), HCT116(B) and SW480(C) cells. No promoter activity was detected within 2kb sequences upstream of miR-483. Cell lines were co-transfected with pGL3-483P containing sequences upstream miR-483(483P); pGL3 basic vector without promoter as a negative control (NC) and pGL3 control vector as a positive control (PC). These vectors were co-transfected with pRL-TK. NS, not statistically significant; ***, p<0.001 determined by One-Way ANOVE test.

Figure 4: Expression levels of miR-483-3p and miR-483-5p in serum samples from CRC patients (n=55) and normal controls (n=31). The miRNA expression levels were assessed by RT-qPCR and normalized by miR-16. The Mann Whitney test was used to determine statistical significance. A. No significant differences in serum miR-483-3p levels were found between CRC patients and normal controls (p<0.05). B. A significant difference was found in serum miR-483-5p level between CRC patients and normal controls (p<0.01). Receiver operating characteristics (ROC) curves based on miR-483-3p C. and miR-483-5p D. were plotted to discriminate normal control from CRC patients. MiR-483-3p and miR-483-5p yield an area under the curve (AUC) value of 0.6012 and 0.7120, respectively. The horizontal solid and dot lines in Figure 1A and 1B represent SEM and mean, respectively.
whereas the miR-483-3p AUC was 0.6012 (95% CI: 0.4694–0.7329; p=0.1219, Figures 4C), indicating that serum miR-483-5p might serve as a potential biomarker for discriminating CRC from normal controls. At the cut-off value of less than 22.15, the sensitivity and the specificity of miR-483-5p were 80.65% and 60%, respectively.

**miR-483-3p suppressed DLC-1 expression and promoted proliferation of CRC cells**

To study the biological function of miR-483 in colorectal cancer, we used a gain-of-function approach by transfecting the HCT116 cell line with either chemically synthesized miR-483-3p mimics or control oligo sequence. We showed that transient transfection with this miRNA mimic caused changes in cellular proliferation at 48h post transfection using the CCK8 assay (Figures 5A).

After examining the Targetscan and miRBase database, we predicted DLC-1 to be a putative target gene of miR-483-3p, which may bind to the 3'UTR sequences of the DLC-1 mRNA. We used Western blot to confirm that DLC-1 expression levels were significantly reduced in CRC tissues compared to the matched normal controls. By comparing the DLC-1 protein levels in 10 primary tumor biopsies to its adjacent non-cancerous tissues using Western blot, we found DLC-1 levels in colorectal cancer tissues to be much lower than the adjacent normal tissues (Figure 5B, Supplementary Figure S2, S3).

To validate whether DLC-1 is targeted by miR-483-3p, a dual luciferase reporter assay was performed using constructs in which wild type and mutated sequences were cloned into the reporter vectors (pMIR-WT-3'UTR and pMIR-MUT-3'UTR). When HCT116 cells were co-transfected with targeting vectors pMIR-WT-3'UTR and miR-483-3p mimics, luciferase activities were significantly reduced compared to cells transfected with control sequences (Figure 5C). However, when the seed regions of the targeting site were mutated (pMIR-MUT-3'UTR), the effects of miR-483-3p on luciferase activity were abolished (Figure 5D), suggesting that miR-483-3p may specifically suppress the DLC-1 gene expression, at least in part, by directly binding to its 3'UTR. To further confirm the inhibitory effect of miR-483-3p on DLC-1 and its oncofunction, a colony formation experiment was performed using SW480 cells which were transfected with either miRNA483-3p antagonist or control antagonist. The results showed that transfection of miRNA483-3p antagonist induce expression of DLC-1 and inhibit cancer cell growth (Figure 6), further verifying the oncofunction of miR-483-3p.

**DISCUSSION**

In this study, we investigated the overexpression of IGF2 intron-derived miR-483 in tissues and serums of CRC patients and explored the molecular mechanisms by which overexpressed miR-483 predisposes to colorectal cancer. In line with their enhanced expressions in primary tumor specimens, miR-483-5p were also readily detected at high levels in the serum samples of CRC patients, but there was no significant difference in miR-483-3p levels between CRC patient serum and normal control serum. Based on the ROC curves, we selected cut-off values that best discriminated CRC patients from healthy individuals. Tissue miR-483-3p was found to have a sensitivity of 76.62% and a specificity of 62.34%, whereas miR-483-5p had a sensitivity of 51.59% and a specificity of 84.42% for CRC detection. At the cut-off value of less than 22.15 for serum miR-483-5p, the sensitivity and the specificity were 80.65% and 60%, respectively. We showed that miR-483-3p could promote CRC cell proliferation and suppress DLC-1 expression by directly binding the 3'UTR of mRNA. Finally, we found that transfection of miR-483-3p antagonist could induce the expression of DLC-1 and inhibit cancer cell growth. It should be noted that the miR-483-3p mimic had less of an effect on cell proliferation than miR-483-3p antagonist. This may be attributed to the HCT116 cells used to testing, which is a malignantly proliferating cell line.

Many studies have shown that intronic miRNAs are coexpressed with their host genes and play a similar role as the host genes [19, 20]. Our results showed that there was undetectable promoter activity in a 2kb fragment upstream miR-483, suggesting that miR-483 may be co-transcribed with the IGF2 gene driven by the IGF2 promoter. In addition, there was a positive correlation between miR-483 and IGF2, both of which were increased in CRC tissues. These results allow us to propose that miR-483 may be coexpressed with its host gene, IGF2. IGF2 has been reported to be involved in the development of many tumors, including Wilms' tumor, hepatocellular carcinoma, breast cancer, bladder cancer, prostate cancer, colorectal cancer, etc. [21-23]. Our group and other labs previously reported that abnormal imprinting or loss of imprinting (LOI) is widely recognized as an important mechanism by which the IGF2 gene promotes carcinogenesis [6-8, 24-29]. This study provides new insight into the mechanism of IGF2 oncofunction and suggests that the LOI or overexpression of IGF2 may, at least in part, mediate oncoeffect through the overexpression of miR-483. In other words, the mechanism by which IGF2 causes carcinogenesis may be at least partially attributed to aberrantly increased miR-483 expression. When this new mechanism was identified to involve in CRC tumorigenesis, we cannot rule out other genetic and/or epigenetic etiologies for CRC due to heterogeneity of cancers.

The first study on miRNAs in colorectal cancer was published in 2002, when miR-143 and miR-145 were identified as novel dysregulated miRNAs [30]. Since then, a lot of other miRNAs have been reported to be involved in carcinogenesis. Tumor-derived miRNAs were
miRNAs were then found to exhibit a higher stability over mRNAs in both plasma and serum. Later, miRNAs were also found to exist in a more resilient form which can resist RNase activity [31]. This will allow for a sufficient amount of time for the sample to be transferred to a laboratory for

Figure 5: miR-483-3p promoted cell proliferation by specifically targeting DLC-1 3’UTR. A. transfection with miR483-3p mimics promoted cell proliferation. Cell viability was determined at 48h after transient transfection with miR-483-3p mimics or negative control (NC) by CCK8 assay (*p<0.05, non-parametric t test); B. Western blot analysis showed lower DLC-1 expression levels in CRC tissues than adjacent normal tissues(N); C. Sequence-specific suppression of DLC-1 expression by miR-483-3p mimics, NC represents negative control; D. miR-483-3p mimics could not bind mutant sequences in DLC-1 3’UTR. The WT sequences and mutant sequences in DLC-1 3’UTR were cloned into pMIR-GLO vector (pMIR-WT-3’UTR and pMIR-MUT-3’UTR). E. miR-483-3p binding sequences in DLC-1 3’UTR are shown on top, miR-483-3p sequences are shown in the middle, and DLC-1 3’ UTR mutant sequences are shown on the bottom. Each of these constructs were transfected into HCT116 cells together with miR-483-3p mimics or negative control sequences and measured after 48h, and normalized using Rluc expression levels as control (*, p<0.05, non-parametric t test; NS, p<0.05).
testing, and ensure that subsequent quantitative analysis is less likely to be affected by biomarker degradation. Given that aberrantly expressed blood miRNAs were closely associated with tumor detection, regardless of their derivation, circulating miR-483 would be a good candidate for potential noninvasive biomarker of CRC.

In conclusion, our study evaluated the feasibility of using tissue miR-483-3p, miR-483-5p and serum miR-

![Figure 6: Transfection with miRNA483-3p antagonim induced DLC-1 expression and inhibited cell growth. (A) Transfection with miRNA483-3p antagonim induced DLC-1 expression in SW480 Cells. SW480 cells were transfected with either 50nM miRNA483-3p antagonim or negative control antagonim (NC). Immunoblot analysis was performed in SW480 cells transfected with miRNA483-3p antagonim using antibodies against DLC-1 and β-actin; (B) Inhibition of colony formation in SW480 cancer cells transfected with miR-483-3p antagonim. Cells were stained with crystal violet solution and the number of colonies was counted; (C) The colony formation on the culture wells]
483-5p as markers for the detection of CRC. We showed that serum miR-483-5p has an acceptable sensitivity for the detection of CRC, making it a potential non-invasive biomarker for CRC screening. Furthermore, by suppressing its target DLC-1 gene and inducing CRC cell proliferation, miR-483-3p may provide a new target for CRC therapy.

MATERIALS AND METHODS

Patients

Seventy seven CRC patients with newly diagnosed colorectal cancer and 31 healthy subjects were recruited. Primary tumor biopsies and adjacent non-cancerous colonic tissues (at least 5 cm away from the tumor) from all 77 patients with CRC were collected. Pre-operative serum samples were collected from 55 of these CRC patients. Patients were excluded if they underwent chemotherapy or radiotherapy before blood sampling. Tumors were staged according to the tumor-node-metastasis (TNM) staging system of UICC. Serums from 31 age-matched healthy subjects were collected as the control group based on negative test results which included blood test, abdominal ultrasound examination, rectal exam, fecal occult-blood testing, chest X-ray, CT scan and colonoscopy. None of these controls had previously been diagnosed with any types of malignancy (Supplementary Table S1).

This study was approved by the Review Board of Nanjing Drum Tower Hospital (protocol number 20130086).

Cell culture and transfection

HEK293T, HCT116, and SW480 cell lines were cultured with Iscove’s modified Dulbecco’s, McCoy’s 5A and RPMI 1640 medium (HyClone, USA), respectively, supplemented with 10% fetal bovine serum (FBS, Invitrogen, USA) and antibiotics (100 IU/ml penicillin and 100 μg/ml streptomycin) at 37°C in a 5% CO2 atmosphere. Chemically synthesized RNAs including miR-483-3p mimics, negative control, and its inhibitor were obtained from Ruibo biosciotech (Ruibo biotechnology, China). Transfection of miRNAs and vectors was performed with Lipofectamine 2000 (Invitrogen) following the procedures of the manufacturer.

Tissue and serum sample processing and RNA isolation

All tissue samples were collected during surgery, immediately snap-frozen in liquid nitrogen, and stored at −80°C until RNA extraction. Total RNA was isolated using Trizol (Invitrogen) according to the instructions of the manufacturer.

Peripheral blood was collected in tubes containing separating gel and clot activator and centrifuged at 3500g for 10 min at 4°C and the supernatants were transferred to Eppendorf tubes. A second centrifugation at 12,000g for 10 min at 4°C was performed to completely remove all cellular components. The serum was then aliquoted and stored at −80°C until RNA extraction. All blood samples were processed within 8 h after they were obtained. Total serum RNA was isolated from 400μl serum and eluted in 100μl of RNase-free water using a mirVana™ miRNA isolation kit (Applied Biosystems, shanghai) following the manufacturer’s protocol for blood samples.

RT-qPCR

Individual miRNA tests were performed on independent sets of serum or tissue samples using a two-step procedure. Mature miRNA expression was assayed using the TaqMan MicroRNA assay (Applied Biosystems). For serum miR-483-3p and miR-483-5p detection, miR-16 serum level (PN4427975) was used as the normalized control. First, 10ng of total RNA isolated from 400μl of serum sample or 500ng of total RNA isolated from tissue was subjected to RT using a miRNA specific primer and the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). In brief, RT was conducted in a scaled-down RT reaction volume of 7.5μl, which contained 2.08μl of water, 0.75μl of 10×RT Reverse Transcription buffer, 0.095μl of RNase inhibitor (20U/μl), 0.075μl of dNTPs with dTTP, 0.5μl of Multiscribe™ reverse transcriptase (50 U/μl), 1.5μl of miRNA specific stem-loop RT primer (Applied Biosystems) and RNA preparations. RT was carried out on a Master cycler Epgradient at 16°C for 30 min, 42°C for 30 min and 85°C for 5 min. Thereafter, real-time qPCR was performed using a TaqMan MicroRNA assay (Applied Biosystems) to quantify the individual miRNAs as described previously. The 10μl real-time reaction contained 2.5μl of 1:3 diluted RT product, 5μl of 2X TaqMan® Universal Master Mix II (No AmpErase®, UNG, PN4440040), and 0.5μl of 20X TaqMan® assay which contained the forward and reverse primers as well as the TaqMan® probe. Real time PCR was carried out on an ABI PRISM 7300 sequence detection system at 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

Real-time RT-qPCR for mRNA was performed using 500ng of total RNA isolated from tissue according to the instructions of the manufacturer (Takara). Real-time PCR reaction was performed using the TaqMan Gene expression assay instrument. The 10μL PCR reaction included 2μl of 1:3 diluted RT reverse transcription product, 5μl of 2X TaqMan® Gene Expression Master Mix (No AmpErase® UNG, PN4369016), and 0.5μl of 20X TaqMan® assay which contained the forward and reverse primers as well as the TaqMan® probe. The reactions were incubated in a 96-well PCR plate at 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. TaqMan gene expression assays were performed for IGF2 genes and endogenous reference control gene GAPDH using primers and probes (Hs01005963_m1, Hs03929097_g1) obtained from Applied Biosystems.

After completion of the RT-qPCR, the threshold value was manually set above the baseline displayed in the amplification plot. Relative quantification of gene expression was evaluated by utilizing the comparative cycle threshold (Ct). The Ct values for each mature miRNA reaction were subtracted from the respective Ct value of the RNU6B control for tissue samples and the miR-16 control for serum samples to obtain the ΔCt value. The Ct values for each mRNA reaction were subtracted from the respective Ct value of the GAPDH control to calculate the ΔCt value. The largest ΔCt value was arbitrarily used as a constant and was subtracted from all the other ΔCt values to determine the ΔΔCt value. Fold changes were then generated for each mRNA and mature miRNA by calculating 2^−ΔΔCt. All qPCR reactions were performed in triplicate and all Ct values greater than 35 from the real-time PCR assays were treated as 35.

Luciferase assays and vectors

A fragment of about 2 kb sequences upstream of miR-483, which was assumed to have promoter activity, was amplified by PCR using primers (see Supplementary Table S2) containing the Nhe1 and Xho1 restriction enzyme sites. PCR product was purified, digested, and directly inserted into the pGL3 vector (Promega Corporation, Madison, WI), named pGL3-483P. The pGL3 basic vector was used as negative control and the pGL3 control vector was used as positive control. These vectors with pRL-TK were co-transfected into SW480, HCT116, and 293T cells, respectively.

To generate the pMIR-DLC1-3’UTR construct containing the putative binding site for miR-483-3p within DLC1 3’UTR, human gDNA from 293 cells were used as template and a 660 bp fragment was amplified by PCR using the primers listed in Supplementary Table S2 and a 660 bp fragment was amplified by PCR using the primers listed in Supplementary Table S2 and was cloned into the pMIR-GLO vector (Promega). We also generated a pMIR-DLC1-3’UTR mutant in which the putative binding site was deleted, named pMIR-GLO-MUT-DLC1. The constructs were confirmed by Sanger sequencing. Each construct was co-transfected into HCT116 cells with 50 nM miR-483 mimics, inhibitor (antisense) or negative control (NC), and 200ng pMIR-GLO-WT-DLC1 or pMIR-GLO-MUT-DLC1 vector. Transfection was performed in OPTI-MEM I (Invitrogen) medium using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol. Firefly luciferase activity was measured at 48 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega, USA) which was normalized using Rluc expression level.

Western blot analysis

Protein was extracted using RIPA buffer (1mM MgCl2, 10 mM Tris–HCl pH 7.5, 1% Triton X-100, 0.1%SDS, 1% NP-40) and the protein samples were either used immediately or stored at −20°C before use. β-actin was used as the loading control. Total protein extracts were separated by 10% SDS–PAGE gels and transferred to PVDF membranes. The level of DLC-1 expression was evaluated using an anti-DLC-1 antibody (1:200, mouse monoclonal anti-human; BD Bioscience). Bands were developed by way of enhanced chemiluminescence reagent and were detected using an auto-exposure system.

Cell proliferation assays

HCT116 cells were seeded in a 96-well plate at a density of 1×10⁴ cells per well, incubated overnight, and then transfected with either negative control or miR-483-3p mimic through Lipofectamine 2000 (Invitrogen, USA) and cultured at 37°C and 5% CO2 for 48 hours. In vitro growth was measured using the Cell Counting Kit (CCK8) (Dojindo Laboratories, Kumamoto, Japan). The optical density at 450 nm was measured using a Microplate Reader (Bio-Rad, Hercules, CA), and the proliferation index was calculated: experimental OD value/control OD value. The experiment is independently repeated three times.

Colony formation

HEK293T cells were cultured in DMEM medium supplemented with antibiotics and 10% fetal bovine serum. For colony formation, 4×10⁴ HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen, USA) with either 50nM miRNA-483-3p antagomir or 50nM NC antagomir (RiboBio Co. Ltd., Guangzhou, China) according to the manufacturer’s instructions. Twenty four hours later, 50 cells were seeded in 6-well tissue culture plates and continued to culture for 2 weeks. The cells were then stained with crystal violet-formalin solution for 10 min and counted.

Statistical analysis

The difference in mRNA or miRNA expression levels between paired tissue samples was calculated using the Wilcoxon matched-pairs test. Correlations between independent samplings and RT-qPCR of IGF2 and miRNA were determined by the Spearman correlation test. The Mann–Whitney test was performed to determine the significance of serum miRNA levels. The area under the curve (AUC) for tissue and serum microRNAs was calculated using Receiver Operator Characteristic (ROC) analysis. P values <0.05 were considered to be statistically significant. The statistical analysis was performed with software SPSS version 16.0 and graphs were generated using Graphpad Prism 5.0.
ACKNOWLEDGMENTS

The authors would like to thank the study participants who kindly agreed to provide tissues and blood for analysis.

CONFLICTS OF INTEREST

The authors have declared that no any potential conflicts that are relevant to the manuscript.

GRANT SUPPORT

This study was supported by NSFC (81171965, 81372237, 91540117), China 973 program (2012CB517605) and the Priority Academic Program for Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine) to HC.

REFERENCES

1. Miller S and Steele S. Novel molecular screening approaches in colorectal cancer. J Surg Oncol. 2012; 105:459-467.
2. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Formari F, Zanesi N, Alder H, D’Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM and Negrini M. Oncogenic Role of miR-483-3p at the IGF2/483 Locus. Cancer Research. 2010; 70:3140-3149.
3. Koufos A, Hansen MF, Lampkin BC, Workman ML, Copeland NG, Jenkins NA and Cavenee WK. Loss Of Alleles at Loci on Human Chromosome-11 during Genesis Of Wilms Tumor. Nature. 1984; 309:170-172.
4. Orkin SH, Goldman DS and Sallan SE. Development of homozygosity for chromosome 11p markers in Wilms’ tumour. Nature. 1984; 309:170-172.
5. Reeve AE, Housiaux PJ, Gardner RJ, Chewings WE, Grindley RM and Millow LJ. Loss of a Harvey ras allele in sporadic Wilms’ tumour. Nature. 1984; 309:174-176.
6. Cui H, Horon IL, Ohlsson R, Hamilton SR and Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998; 4:1276-1280.
7. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998; 4:1276-1280.
8. Cruz-Correa M, Cui H, Giardiello FM, Powe NR, Hyland L, Robinson A, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X and Feinberg AP. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology. 2004; 126:964-970.
9. Luo XY, Burwinkel B, Tao S and Brenner H. MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? Cancer Epidemiology Biomarkers & Prevention. 2011; 20:1272-1286.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
11. Ma N, Wang X, Qiao Y, Li F, Hui Y, Zou C, Jin J, Lv G, Peng Y, Wang L, Huang H, Zhou L, Zheng X and Gao X. Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner. Mol Cell Endocrinol. 2011; 333:96-101.
12. Ng EKO, Chong WWS, Jin H, Lam EKY, Shin VY, Yu J, Poon TCW, Ng SSM and Sung JY. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Int J Oncol. 2015; 46:539-547.
13. Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K and Satoh K. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 2014; 43:110-117.
14. Qu X, Zhao M, Wu S, Yu W, Xu J, Li J and Chen L. Circulating microRNA 483-5p as a novel biomarker for survival prediction in multiple myeloma. Med Oncol. 2014; 31:219.
15. Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang SD, Hu YZ, Zhou XX and Jia WH. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chin J Cancer. 2014; 33:300-303.
16. Liao YC and Lo SH.Deleted in liver cancer-1 (DLC-1): A tumor suppressor not just for liver. International Journal Of Biochemistry & Cell Biology. 2008; 40:843-847.
17. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS and Popescu NC. DLC-1: a Rho GTPase-activating protein and tumour suppressor. Journal Of Cellular And Molecular Medicine. 2007; 11:1185-1207.
18. Du XL, Qian XL, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI and Lowy DR. Functional Interaction of Tumor Suppressor DLC1 and Caveolin-1 in Cancer Cells. Cancer Research. 2012; 72:4405-4416.
19. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ and Fernandez-Hernando C. MiR-33 Contributes to the Regulation of Cholesterol Homeostasis. Science. 2010; 328:1570-1573.
20. Najafi-Shoushtari SH, Kristo F, Li YX, Shiota T, Cohen DE, Gerszten RE and Naar AM. MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis. Science. 2010; 328:1566-1569.
21. Chen YW, Boyarchuk V and Lewis BC. Differential Roles of Insulin-like Growth Factor Receptor- and Insulin Receptor-mediated Signaling in the Phenotypes of Hepatocellular Carcinoma Cells. Neoplasia. 2009; 11:835-U177.
22. Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers. 2007; 23:105-112.

23. Vu TH, Nguyen AH and Hoffman AR. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Human Molecular Genetics. 2010; 19:901-919.

24. Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenko VV and Feinberg AP. Loss of imprinting of insulin-like growth factor-II in Wilms’ tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 2001; 61:4947-4950.

25. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL and Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002; 62:6442-6446.

26. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC and Feinberg AP. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998; 91:3144-3147.

27. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013; 20:R321-339.

28. Jelinic P and Shaw P. Loss of imprinting and cancer. Journal Of Pathology. 2007; 211:261-268.

29. Kaneda A and Feinberg AP. Loss of imprinting of IGF2: A common epigenetic modifier of intestinal tumor risk. Cancer Research. 2005; 65:11236-11240.

30. Michael MZ, O’Connor SM, Pellekaan NGV, Young GP and James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Molecular Cancer Research. 2003; 1:882-891.

31. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW,Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings Of the National Academy Of Sciences Of the United States Of America. 2008; 105:10513-10518.

32. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boulwood J, Wainscoat JS, Hatton CSR and Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal Of Haematology. 2008; 141:672-675.